1 / 0

H.I.G. BioVentures

H.I.G. BioVentures. July 29, 2011. H.I.G. Capital – Corporate Overview. H.I.G. is one of the leading private equity firms in the small-cap segment of the market Founded in 1993; over $ 9 Billion under management More than 200 investment professionals Offices:

koen
Télécharger la présentation

H.I.G. BioVentures

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. H.I.G. BioVentures July 29, 2011
  2. H.I.G. Capital – Corporate Overview H.I.G. is one of the leading private equity firms in the small-cap segment of the market Founded in 1993; over $9Billion under management More than 200 investment professionals Offices: North America: Miami, Atlanta, Boston, San Francisco, New York, Maryland Europe: London, Paris, Hamburg H.I.G. Funds: Venture/Growth Investments: H.I.G. BioVentures; H.I.G. Growth Partners Buyout Investments: U.S. LBO, Europe LBO Distressed Investments: Bayside Capital (debt) Public Equities: Brightpoint Capital “Institutionalized” management structure/processes with strong financial staff/controls, legal/compliance, IT support, and risk management procedures in place Differentiated, value-added strategy has resulted in superior track record 2
  3. H.I.G. BioVentures – Background Established dedicated life science focus in 2004 : Approximately $350 Million in capital under management $150 Million committed to existing portfolio companies Currently investing out of H.I.G. BioVentures II Experienced team focused exclusively on life science investing Sectors: biopharmaceuticals, medical devices, diagnostics H.I.G. BioVentures is the lead or co-lead investor in all investments Active board representation in all companies 7
  4. H.I.G. BioVentures – Team Four senior investment professionals with collectively more than 30 years of venture capital investing experience The H.I.G. BioVentures team has complementary backgrounds covering Research and intellectual property Product and process development Business development Operations Finance Sales and marketing The H.I.G. BioVentures team also has a deep network of advisors, co-investors, corporate leaders, and technical consultants to leverage during due diligence and on behalf of portfolio companies 8
  5. H.I.G. BioVentures – Industry Leadership The H.I.G. BioVentures team is active with numerous academic and non-profit organizations Boards of regional venture capital organizations: Mid-Atlantic Venture Association (MAVA), FL Bio, GA Bio Board and committee participation at national and regional conferences: Bio-Investor Forum, Mid-Atlantic Bio, Southeast Bio Investor Forum, FL Venture Forum, Midwest Healthcare Investor Network Board/advisory member for universities and entrepreneurial organizations : Johns Hopkins Alliance, Maryland Technology Enterprise Institute, North Texas Enterprise Corporation, Texas Bioscience Council, Coulter Foundation (Emory, Ga. Tech), Sid Martin Biotechnology Incubator , Univ. Miami, Univ. Florida, Univ. Delaware Research Foundation, Virginia CIT Gap Fund Investment Board (affiliated with all Virginia Universities), Enterprise Florida Not-for-profit boards : Adventist Healthcare Speaker/panelist : Multiple national and regional conferences including BIO 2011 9
  6. H.I.G. BioVentures – Aaron Davidson Executive management at Eli Lilly and Company Business development Sales and marketing Finance General management Venture capital experience at Ventures West Leading Canadian healthcare investor Operating history at Eli Lilly and Company and venture-backed SYN-X Pharma Broad network in the pharmaceutical and biotechnology industry as well within the venture capital community. M.B.A., Harvard Business School B.Comm., McGill University adavidson@higbio.com (305) 379-2322 10
  7. H.I.G. BioVentures – Bruce Robertson Operating experience in both business development and R&D IGEN (acquired by Roche) W.R. Grace Venture capital experience at Toucan Capital and GIV Venture Partners Extensive relationships in the Mid-Atlantic’s financial, entrepreneurial and scientific/academic community Well-connected within broad venture capital community M.B.A., Harvard Business School Ph.D., University of Delaware (Biomedical Engineering) B.S.E., University of Pennsylvania brobertson@higbio.com (305) 379-2322 11
  8. H.I.G. BioVentures – Michael Wasserman Operating experience in entrepreneurial/venture- backedbiotechnology Founder and VP, Business Development at CELLutions Biosystems (acq.by Cedarlane Labs) Background in early-stage technology transfer and development as a Principal with Innovations Foundation Clinical drug development and regulatory expertise based on tenure at Advanced Therapeutics Extensive network and deal flow resources in multiple geographies – Southeast, Midwest, Texas, Ohio, etc. Ph.D., University of Toronto (Pharmacology) B.S., McGill University mwasserman@higbio.com (305) 379-2322 12
  9. H.I.G. BioVentures – Michael Gutch Venture Capital experience at Lilly Ventures, Eli Lilly and Company Member of the Corporate Finance & Investment Banking group at Eli Lillyand Company Post-doctoral research experience at Cold Spring Harbor Labs and UCSF Strong associations in the pharmaceutical and entrepreneurial communities and networked throughout the Midwest and Northwest M.B.A., Indiana University Ph.D., State University of New York (Molecular & Cellular Pathology) B.S., Alfred University mgutch@higbio.com (305) 379-2322 13
  10. H.I.G. BioVentures – Investment Strategy Investment Strategy Validation & Differentiation Areas of Unmet Medical Need Efficient Clinical Development Broad Source of Deal Flow Extensive networks outside of CA and MA resulting in proprietary deal flow Approximately 80% of investments in “secondary geographies” Clear and meaningful clinical end-points Short clinical development timelines to demonstrate proof-of-concept in appropriate patient groups Scientific and clinical validation well established Differentiation from current standard of care Regulatory precedent established Large, attractive markets Significant unmet medical needs Chronic or acute care high value per patient disease indications 14
  11. H.I.G. BioVentures – Partnering with Industry H.I.G. BioVentures values its long-term relationships with the pharma and medical device industries H.I.G. BioVentures has: Co-invested with corporate venture capital groups such as MedImmune Ventures, SROne, Novo A/S Strong relationships with most pharmaceutical and med-tech corporate venture capital and business development groups Ongoing discussions with CVC and BD groups on existing portfolio companies and new deal opportunities H.I.G. BioVentures portfolio companies have recently completed transactions with: 17
  12. H.I.G. BioVentures – Summary Dedicated to investing in high potential life sciences companies Team of experienced investment professionals with deep domain knowledge Proprietary deal flow developed through a broad relationship network Ability to leverage the more than 200 investment professionals across the H.I.G. Capital platform Building business relationships with pharmaceutical, biotechnology, and medical device companies 18
  13. Questions?
More Related